Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Kohlmann

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Leukemia|November 26, 2011
Landscape of TET2 mutations in acute myeloid leukemiaS Weissmann, T Alpermann, V Grossmann, et al.
Blood Cancer Journal|January 14, 2014
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemiaS Weber, T Alpermann, F Dicker, et al.
Leukemia|September 13, 2014
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL statusM Schmidt, J Rinke, V Schäfer, et al.
Leukemia|May 8, 2013
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristicsV Grossmann, U Bacher, C Haferlach, et al.
Science (New York, N.Y.)|January 11, 2000
Nitric acid trihydrate (NAT) in polar stratospheric cloudsC Voigt, J Schreiner, A Kohlmann, et al.
Leukemia|March 30, 2011
Gene expression profiling in MDS and AML: potential and future avenuesK Theilgaard-Mönch, J Boultwood, S Ferrari, et al.
Leukemia|September 29, 2012
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcomeS Schnittger, C Eder, S Jeromin, et al.
Leukemia|February 13, 2016
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patientsS Soverini, C De Benedittis, C Papayannidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancerJ-C Soria, A Fülöp, C Maciel, et al.
Leukemia|May 12, 2016
The role of the RAS pathway in iAMP21-ALLS L Ryan, E Matheson, V Grossmann, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Leukemia|November 26, 2011
Landscape of TET2 mutations in acute myeloid leukemiaS Weissmann, T Alpermann, V Grossmann, et al.
Blood Cancer Journal|January 14, 2014
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemiaS Weber, T Alpermann, F Dicker, et al.
Leukemia|September 13, 2014
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL statusM Schmidt, J Rinke, V Schäfer, et al.
Leukemia|May 8, 2013
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristicsV Grossmann, U Bacher, C Haferlach, et al.
Science (New York, N.Y.)|January 11, 2000
Nitric acid trihydrate (NAT) in polar stratospheric cloudsC Voigt, J Schreiner, A Kohlmann, et al.
Leukemia|March 30, 2011
Gene expression profiling in MDS and AML: potential and future avenuesK Theilgaard-Mönch, J Boultwood, S Ferrari, et al.
Leukemia|September 29, 2012
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcomeS Schnittger, C Eder, S Jeromin, et al.
Leukemia|February 13, 2016
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patientsS Soverini, C De Benedittis, C Papayannidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancerJ-C Soria, A Fülöp, C Maciel, et al.
Leukemia|May 12, 2016
The role of the RAS pathway in iAMP21-ALLS L Ryan, E Matheson, V Grossmann, et al.
Pageof 5